Site Search

AUGUSTA – Last week, The Appropriations and Financial Affairs Committee voted to fund LD 1577  An Act to Require Health Insurance Coverage for Biomarker Testing.  This legislation, which passed both House and Senate chambers earlier this month with broad ... first and moved to ensure more Mainers have access to biomarker testing. With this medical advancement, many patients can receive personalized care, specific to their individual disease, that can eliminate unnecessary and costly treatments for some patients. “Now, we’re down to the wire and it’s time to look ahead. After two years of advocacy by public health groups, providers and patients across Maine, the only thing that stands between ensuring insurance coverage of this game changing ...

... to act on Assembly Bill 1673 / Senate Bill 1196. “In order to maintain our state’s role as a national leader in medical innovation, cancer care and public health, we must prioritize legislation such as Assembly Bill 1673 / Senate Bill 1196. In doing so, we can work to improve health outcomes, patient quality of life and—in some cases—reduce costs. “The victory in Texas should be eye-opening to legislators across ...

... the last few decades and is increasingly important in the treatment of other conditions, providing access to targeted treatment and tailoring care to a person’s individual disease. Targeted therapies often result in improved quality of life and survivorship. For example, patients with ... and the New York State Senate for approving this legislation. We urge the Assembly to follow suit and take this critical step towards reducing health inequities and improving health outcomes." In 2023, approximately 31,320 New Yorkers will die from cancer. Improved access to biomarker testing can connect more patients to ...

... today Senate Commerce Committee members took a meaningful step toward expanding access.” The power of biomarker testing extends beyond cancer care to the treatment of diseases such as arthritis, other autoimmune conditions and rare diseases. Peggy Lotkowictz dealt with severe discomfort ... I’ll be using this energy to urge lawmakers to gift patients this incredible resource in 2025.” There is consensus across medical and public health leaders that biomarker testing is increasingly important to reducing risk of death, improving quality of life for many cancer patients and ... advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and advanced proven tobacco control measures. We stand with our volunteers, working to make cancer a top priority for policymakers in ...